1198785-75-9

Upstream product

• 932-31-0 ortho-tolylmagnesium bromide 
• 400-31-7 1,1,1-trifluoro-4-methyl-pent-3-en-2-one 

Downstream Products

• 1562399-44-3 3-hydroxy-5-methyl-5-o-tolyl-3-trifluoromethylhexanoic acid 
• 1562399-45-4 3-hydroxy-5-methyl-5-o-tolyl-3-trifluoromethylhexanoic acid methyl ester 
• 1562399-47-6 1,1,1-trifluoro-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-4-(2-methylphenyl)pentan-2-ol 
• 1562399-46-5 C₁₉H₂₉F₃O₃Si 
• 1429301-72-3 (R)-6-(2-methylphenyl)-6-methyl-4-(trifluoromethyl)-1-(trimethylsilyl)hept-1-yn-4-ol 

Relevant academic research and scientific papers

Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects

Synthesis and structure-activity relationship (SAR) of a series of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain "diazaindole" moieties and display different transcriptional regulatory profiles in vitro and are

GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

Compounds of Formula I wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.